Literature DB >> 19130462

Survival after hepatic resection of colorectal cancer metastases: a national experience.

Douglas J Robertson1, Therese A Stukel, Daniel J Gottlieb, Jason M Sutherland, Elliott S Fisher.   

Abstract

BACKGROUND: Most estimates of short- and long-term survival after hepatic resection of colorectal cancer metastases are derived from surgical case series. For the current report, the authors used Medicare data to investigate operative mortality and long-term survival in a national sample and examined the factors associated with survival.
METHODS: Data were analyzed from Medicare enrollees (age >or=65 years) who were admitted to hospital between January 1, 2000 and December 31, 2004 with a primary diagnosis of colorectal cancer with resection. The sample was restricted to patients who subsequently underwent hepatic resection for liver metastases. The Medicare Denominator File was used to determine operative mortality and long-term survival and the factors that were associated with those outcomes.
RESULTS: Of the 306,061 Medicare beneficiaries who were diagnosed with colorectal cancer, 3957 patients were identified who underwent hepatic resection for liver metastases. The crude 30-day and 90-day mortality rates were 4% and 8.2%, respectively, and the 5-year survival rate was 25.5%. Advancing age (hazards ratio [HR], 1.83; 95% confidence interval [95% CI], 1.32-2.53 for age >or=80 years vs ages 65-69 years), comorbid disease (HR, 1.40; 95% CI, 1.06-1.85 for Charlson >or=5 vs Charlson 0), and synchronous colon/hepatic resection (HR, 2.46; 95% CI, 1.89-3.20 for synchronous vs metachronous resection) were associated with worse 90-day mortality. Similarly, long-term mortality was associated with age (HR, 1.36; 95% CI, 1.18-1.56), comorbid disease (HR, 1.51; 95% CI, 1.36-1.69), and synchronous colon/hepatic resection (HR, 1.37; 95% CI, 1.24-1.51 for synchronous vs metachronous resection).
CONCLUSIONS: In this national study, short- and long-term survival was worse than that reported in surgical case series. Subgroups at high risk for worse outcomes include the extreme elderly and those undergoing synchronous colon and hepatic resection. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19130462      PMCID: PMC2740982          DOI: 10.1002/cncr.24081

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model.

Authors:  Lorenzo Capussotti; Luca Vigano'; Alessandro Ferrero; Roberto Lo Tesoriere; Dario Ribero; Roberto Polastri
Journal:  Ann Surg Oncol       Date:  2007-01-04       Impact factor: 5.344

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

4.  Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis.

Authors:  S M Beard; M Holmes; C Price; A W Majeed
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

5.  Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer.

Authors:  Armin Thelen; Sven Jonas; Christoph Benckert; Antonino Spinelli; Enrico Lopez-Hänninen; Birgit Rudolph; Ulf Neumann; Peter Neuhaus
Journal:  Int J Colorectal Dis       Date:  2007-02-21       Impact factor: 2.571

6.  Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma.

Authors:  J S Bolton; G M Fuhrman
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

7.  Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy.

Authors:  Y Sugawara; J Yamamoto; S Yamasaki; K Shimada; T Kosuge; M Makuuchi
Journal:  Surgery       Date:  2001-04       Impact factor: 3.982

8.  Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy.

Authors:  John T Mullen; Dario Ribero; Srinevas K Reddy; Matteo Donadon; Daria Zorzi; Shiva Gautam; Eddie K Abdalla; Steven A Curley; Lorenzo Capussotti; Bryan M Clary; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2007-02-15       Impact factor: 6.113

9.  Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis.

Authors:  Srinevas K Reddy; Timothy M Pawlik; Daria Zorzi; Ana L Gleisner; Dario Ribero; Lia Assumpcao; Andrew S Barbas; Eddie K Abdalla; Michael A Choti; Jean-Nicolas Vauthey; Kirk A Ludwig; Christopher R Mantyh; Michael A Morse; Bryan M Clary
Journal:  Ann Surg Oncol       Date:  2007-09-01       Impact factor: 5.344

10.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

View more
  55 in total

Review 1.  Challenges in the management of older patients with colon cancer.

Authors:  Efrat Dotan; Ilene Browner; Arti Hurria; Crystal Denlinger
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.

Authors:  Xi Ai; Yanhui Wu; Wei Zhang; Zhanguo Zhang; Guannan Jin; Jianping Zhao; Jingjing Yu; Youzhi Lin; Wanguang Zhang; Huifang Liang; Pran K Datta; Mingzhi Zhang; Bixiang Zhang; Xiaoping Chen
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 3.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

4.  Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis.

Authors:  Chien-Hsin Chen; Mao-Chih Hsieh; Wilson T Lao; En-Kwang Lin; Yen-Jung Lu; Szu-Yuan Wu
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

Review 5.  Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives.

Authors:  Matthias F Häfner; Jürgen Debus
Journal:  Visc Med       Date:  2016-06-16

6.  Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-05       Impact factor: 3.621

7.  Validation of the peak bilirubin criterion for outcome after partial hepatectomy.

Authors:  Kim M C van Mierlo; Toine M Lodewick; Dipok K Dhar; Victor van Woerden; Ralph Kurstjens; Frank G Schaap; Ronald M van Dam; Soumil Vyas; Massimo Malagó; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  HPB (Oxford)       Date:  2016-07-02       Impact factor: 3.647

8.  Simultaneous colorectal and hepatic procedures for colorectal cancer result in increased morbidity but equivalent mortality compared with colorectal or hepatic procedures alone: outcomes from the National Surgical Quality Improvement Program.

Authors:  Osama H Hamed; Neil H Bhayani; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

9.  Management of potentially resectable colorectal cancer liver metastases.

Authors:  Fausto Meriggi; Paola Bertocchi; Alberto Zaniboni
Journal:  World J Gastrointest Surg       Date:  2013-05-27

Review 10.  Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series.

Authors:  Michael E Egger; Joanna M Ohlendorf; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.